RT Journal Article
SR Electronic
T1 Cerebral Organoids Containing an <em>AUTS2</em> Missense Variant Model Microcephaly
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.02.23.22271091
DO 10.1101/2022.02.23.22271091
A1 Fair, Summer R.
A1 Schwind, Wesley
A1 Julian, Dominic
A1 Biel, Alecia
A1 Ramadesikan, Swetha
A1 Westfall, Jesse
A1 Miller, Katherine E.
A1 Kararoudi, Meisam Naeimi
A1 Hickey, Scott E.
A1 Mosher, Theresa Mihalic
A1 McBride, Kim L.
A1 Neinast, Reid
A1 Fitch, James
A1 Lee, Dean
A1 White, Peter
A1 Wilson, Richard K.
A1 Bedrosian, Tracy A.
A1 Koboldt, Daniel C.
A1 Hester, Mark E.
YR 2022
UL http://medrxiv.org/content/early/2022/02/24/2022.02.23.22271091.abstract
AB Variants in the AUTS2 gene are associated with a broad spectrum of neurological conditions characterized by intellectual disability, microcephaly, and congenital brain malformations. Here, we use a human cerebral organoid (CO) model to investigate the pathophysiology of a heterozygous de novo missense AUTS2 variant identified in a patient with multiple neurological impairments including primary microcephaly and profound intellectual disability. Proband COs exhibit reduced growth, deficits in neural progenitor cell (NPC) proliferation and disrupted NPC polarity within ventricular zone-like regions compared to control COs. We used CRISPR-Cas9-mediated gene editing to correct this variant and demonstrate rescue of impaired organoid growth and NPC proliferative deficits. Single-cell RNA sequencing revealed a marked reduction of G1/S transition gene expression and alterations in WNT-β-Catenin signaling within proband NPCs, uncovering a novel role for AUTS2 in NPCs during human cortical development. Collectively, these results underscore the value of COs to uncover molecular mechanisms underlying AUTS2 syndrome.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe funding of this work was generously supported by the Nationwide Foundation Pediatric Innovation Fund.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The IRB committee of Nationwide Children's Hospital gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors